Alessandro de Souza Prestes

Dr. Alessandro de Souza Prestes

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2008 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
RPRomaiana Picada Pereira
Romaiana Picada Pereira
RFRoselei Fachinetto
Roselei Fachinetto
APAlessandro de Souza Prestes
Alessandro de Souza Prestes
RPRobson Luiz Puntel
Robson Luiz Puntel
GSGloria Narjara Santos da Silva
Gloria Narjara Santos da Silva
João RochaJoão Rocha
João Rocha

1 August 2013 in Toxicology in Vitro
Verified
Journal Article
Closed access
SSSílvio Terra Stefanello
Sílvio Terra Stefanello
APAlessandro de Souza Prestes
Alessandro de Souza Prestes
TOTade Ogunmoyole
Tade Ogunmoyole
SSSyed M. Salman
Syed M. Salman
RSRicardo S. Schwab
Ricardo S. Schwab
FSFelix Alexandre Antunes Soares
Felix Alexandre Antunes Soares

28 October 2010 in Molecules
Verified
Journal Article
Open access
PDF file
AFAndressa Sausen de Freitas
Andressa Sausen de Freitas
APAlessandro de Souza Prestes
Alessandro de Souza Prestes
CWCaroline Wagner
Caroline Wagner
JSJéssie Haigert Sudati
Jéssie Haigert Sudati
Diego AlvesDiego Alves
Diego Alves
João RochaJoão Rocha
João Rocha
Since the successful use of the organoselenium drug ebselen in clinical trials for the treatment of neuropathological conditions associated with oxidative stress, there have been concerted efforts geared towards understanding the precise mechanism of action of ebselen and other organoselenium compounds, especially the diorganyl diselenides such as diphenyl diselenide, and its analogs. Although the mechanism of action of ebselen and other organoselenium compounds has been shown to be related to their ability to generally mimic native glutathione peroxidase (GPx), only ebselen however has been shown to serve as a substrate for the mammalian thioredoxin reductase (TrxR), demonstrating another component of its pharmacological mechanisms. In fact, there is a dearth of information on the ability of other organoselenium compounds, especially diphenyl diselenide and its analogs, to serve as substrates for the mammalian enzyme thioredoxin reductase. Interestingly, diphenyl diselenide shares several antioxidant and neuroprotective properties with ebselen. Hence in the present study, we tested the hypothesis that diphenyl diselenide and some of its analogs (4,4’-bistrifluoromethyldiphenyl diselenide, 4,4’-bismethoxy-diphenyl diselenide, 4.4’-biscarboxydiphenyl diselenide, 4,4’-bischlorodiphenyl diselenide, 2,4,6,2’,4’,6’-hexamethyldiphenyl diselenide) could also be substrates for rat hepatic TrxR. Here we show for the first time that diselenides are good substrates for mammalian TrxR, but not necessarily good mimetics of GPx, and vice versa. For instance, bis-methoxydiphenyl diselenide had no GPx activity, whereas it was a good substrate for reduction by TrxR. Our experimental observations indicate a possible dissociation between the two pathways for peroxide degradation (either via substrate for TrxR or as a mimic of GPx). Consequently, the antioxidant activity of diphenyl diselenide and analogs can be attributed to their capacity to be substrates for mammalian TrxR and we therefore conclude that subtle changes in the aryl moiety of diselenides can be used as tool for dissociation of GPx or TrxR pathways as mechanism triggering their antioxidant activities.

1 April 2018 in Behavioural Processes
Verified
Journal Article
Closed access
Caio MaximinoCaio Maximino
Caio Maximino
DMDaniele L. Meinerz
Daniele L. Meinerz
BFBarbara Dotto Fontana
Barbara Dotto Fontana
NMNathana J. Mezzomo
Nathana J. Mezzomo
FSFlavia V. Stefanello
Flavia V. Stefanello
DRDenis B. Rosemberg
Denis B. Rosemberg

1 September 2012 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
JKJean Paul Kamdem
Jean Paul Kamdem
SSSílvio Terra Stefanello
Sílvio Terra Stefanello
ABAline Augusti Boligon
Aline Augusti Boligon
CWCaroline Wagner
Caroline Wagner
IKIge Joseph Kade
Ige Joseph Kade
João RochaJoão Rocha
João Rocha
Antioxidant activity of the ethanolic extract and fractions from the stem bark of T. catigua was investigated. IC50 (for DPPH scavenging) by T. catigua varied from 9.17 ± 0.63 to 76.42 ± 5.87 mg mL-1 and total phenolic content varied from 345.63 ± 41.08 to 601.27 ± 42.59 mg GAE g-1 of dry extract. Fe2+-induced lipid peroxidation was significantly reduced by the ethanolic extract and fractions. Mitochondrial Ca2+-induced dichlorofluorescein oxidation was significantly reduced by the ethanolic extract in a concentration-dependent manner. Ethanolic extract reduced mitochondrial Dym only at high concentrations (40-100 mg mL-1), which indicates that its toxicity does not overlap with its antioxidant effects. Results suggest involvement of antioxidant activities of T. catigua in its pharmacological properties.

1 July 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
MSMatheus M. dos Santos
Matheus M. dos Santos
GMGabriel T. de Macedo
Gabriel T. de Macedo
APAlessandro de Souza Prestes
Alessandro de Souza Prestes
VLVânia L. Loro
Vânia L. Loro
GHGraciela M. Heidrich
Graciela M. Heidrich
NBNilda De Vargas Barbosa
Nilda De Vargas Barbosa